[1] |
SUN Yinghao, ZANG Shuangyao, YU Wenhui, GUO Shuai, LI Tingting, ZHANG Yi, ZHANG Tingjian, MENG Fanhao.
Effects and Challenges of Pharmacology and Toxicology of Aconitum Diterpenoid Alkaloids
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 601-607.
|
[2] |
CHEN Runji, SUN Xiaorui, HUANG Xin, JIANG Zhenzhou, ZHANG Luyong, WANG Xinzhi, DING Jian.
Dynamic Immunophenotyping of NK Cells in Triptolide-Induced Hepatotoxicity
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 517-522.
|
[3] |
WANG Fengxin, LI Lei, HUANG Xurui, ZHAO Yun, LING Ruby, YANG Yang, LIANG Changhao, ZENG Yuntao, ZHENG Yingjun, TANG Yuanchen, LIU Jiatao, WANG Chengxiang, WEN Tiancai, LI Ping.
Efficacy and Safety of Danshen Decoction in Treatment of Coronary Heart Disease
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 575-579.
|
[4] |
CHEN Huan, LIANG Jun, ZHAO Wei, XIA Qingrong.
Clinical Features and Risk Factors of Liver Injury Induced by Atypical Antipsychotic Drugs
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 410-414.
|
[5] |
LAN Xiaoqian, GUO Wei.
Trough Steady-State Concentration/Dose Ratio and Contributors to Adverse Drug Reactions of Sulpiride
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 420-423.
|
[6] |
WANG Shuan, HUANG Can, QI Lamei.
Establishment and Evaluation of Apatinib-Induced Hypertension Prediction Model Based on Real-World Data
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 429-435.
|
[7] |
TANG Qianhui, ZHANG Haoran, ZHANG Luyong, JIANG Zhenzhou.
Research Progress in Triptolide-Induced Live Injury
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 121-127.
|
[8] |
ZHANG Jing, ZHANG Kai, YI Zhanmiao.
Efficacy and safety of salvianolic acid preparations for adjuvant therapy on related diseases of coronary heart disease, angina and cerebral infarction: a systematic review
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 910-915.
|
[9] |
LIU Qian, LI Bo, SHU Xinyang.
Lanqin oral liquid combined with antibacterial drugs for the treatment of acute tonsillitis: a systematic review and Meta-analysis
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 916-920.
|
[10] |
GAO Xu, PENG Jin’e, FAN Zibo, ZHANG Wei.
Systematic evaluation of clinical features and prognostic outcomes of rifampicin-induced hemolytic anemia
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 671-676.
|
[11] |
WANG Shubo, JIAO Tingting, DONG Hongliang, WANG Bailing, LI Hui.
A model for prediction of risk factors of acute kidney injury induced by voriconazole for injection based on real-world data
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 567-571.
|
[12] |
YANG Bo, WANG Mengjiao, HU Lili, WANG Laicheng, LI Qian, KONG Feifei, LYU Dongmei, SHEN Jiani.
Safety assessment and risk factor analysis of PD-1 immunotherapy in a cohort of 385 patients
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 447-450.
|
[13] |
GAO Yuan, SHI Wei, XIAO Xiaohe, BAI Zhaofang, WANG Jiabo.
Research progress on the animal models of idiosyncratic drug-induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 33-39.
|
[14] |
SHANG Huiying, WEI Xue, CHENG Hongbo, MA Zengchun, TU Bodan, XIAO Chengrong, LIU Xian, GAO Yue.
Hepatotoxic components in Psoraleae Fructus based on high-content screening technology
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 74-82.
|
[15] |
ZHANG Qin, ZHANG Luyong, JIANG Zhenzhou.
Research progress in safety of PPAR agonists
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 950-955.
|